drugset / Trial / NCT05512598
HB0034 in Patients With Generalized Pustular Psoriasis (GPP)
NaSingle-groupOpen-labelTreatment
Summary
This is a study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HB0034 in adult patients with generalized pustular psoriasis (GPP ).
Timeline
- Start
- 2022-11-06
- Primary completion
- 2023-11-15
- Completion
- 2024-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB0034 | Monoclonal antibody | — | — |